ClinicaliQ Trial Snapshot
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer — Recruiting • Phase II • Oncology • NCT05775159.
- What is being tested: Novel immunomodulators administered as monotherapy and in combination with anticancer agents to evaluate their efficacy, safety, and tolerability in advanced hepatobiliary cancer.
- Patient eligibility overview: Participants with advanced hepatobiliary solid tumors meeting specified clinical criteria are enrolled to assess treatment responses across this difficult-to-treat cancer population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Eligibility Snapshot
- : * Age ≥18 years at the time of signing the ICF. * Provision of a signed and dated written ICF. * Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology. * Adequate organ and bone marrow function. * At least 1 measurable not previously irradiated lesion per RECIST 1.1 * Life expectancy of at least 12 weeks at the time of screening. * Willing and able to provide an adequate tumor sample.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.